Opposite effects of Gαi2 or Gαi3 deficiency on reduced basal density and attenuated β-adrenergic response of ventricular Ca2+ currents in myocytes of mice overexpressing the cardiac β1-adrenoceptor.
{"title":"Opposite effects of Gα<sub>i2</sub> or Gα<sub>i3</sub> deficiency on reduced basal density and attenuated β-adrenergic response of ventricular Ca<sup>2+</sup> currents in myocytes of mice overexpressing the cardiac β<sub>1</sub>-adrenoceptor.","authors":"Nour Katnahji, Jan Matthes","doi":"10.1007/s00210-025-03999-y","DOIUrl":null,"url":null,"abstract":"<p><p>Ca<sup>2+</sup> currents (I<sub>CaL</sub>) carried by ventricular L-type Ca<sup>2+</sup> channels (LTCC) are altered in failing hearts, and increased LTCC activity is discussed as a cause of cardiomyopathy. We have shown that lack of the inhibitory G-protein isoform Gα<sub>i3</sub> improves cardiac outcome and survival in a murine heart-failure model of cardiac β<sub>1</sub>-adrenoceptor (β<sub>1</sub>-AR) overexpression (β<sub>1</sub>-tg), while lack of the Gα<sub>i2</sub> isoform was detrimental in the same heart-failure model. Given the potential role of LTCC and their modulation by β-adrenergic signalling, we now analysed ventricular I<sub>CaL</sub> in β<sub>1</sub>-tg mice and in β<sub>1</sub>-tg mice lacking either Gα<sub>i2</sub> or Gα<sub>i3</sub>. Using the patch-clamp technique, we recorded whole-cell I<sub>CaL</sub> in ventricular myocytes freshly isolated from adult mice. Compared to age-matched wild-type littermates, basal I<sub>CaL</sub> was reduced in myocytes from β<sub>1</sub>-tg mice both under basal conditions (- 8.1 ± 1.6 vs. - 5.5 ± 1.5 pA/pF) and upon β-adrenergic stimulation with 1 µM isoproterenol (- 14.3 ± 5.6 vs. - 7.4 ± 1.9 pA/pF). Lack of Gα<sub>i3</sub> normalised basal I<sub>CaL</sub> to nearly wild-type levels (- 7.5 ± 1.6 pA/pF), while β-adrenergic response remained attenuated (- 9.5 ± 3.6 pA/pF). In contrast, the absence of Gα<sub>i2</sub> did not restore basal I<sub>CaL</sub> (- 5.7 ± 1.8 pA/pF), but restored the β-adrenergic response of I<sub>CaL</sub>, with the difference from basal current even exceeding that in wild-type mice (- 12.2 ± 2.9 pA/pF).We propose that by restoring basal I<sub>CaL</sub>, Gα<sub>i3</sub> deficiency might contribute to the restoration of contractility in β<sub>1</sub>-tg mice, while maintaining attenuation of the I<sub>CaL</sub> response upon β-adrenergic stimulation protects against deleterious effects mediated by enhanced β-AR signalling. In contrast, restored and even enhanced I<sub>CaL</sub> response to β-adrenergic stimulation might contribute to detrimental effects of Gα<sub>i2</sub> deficiency observed in β<sub>1</sub>-tg mice previously.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-03999-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Ca2+ currents (ICaL) carried by ventricular L-type Ca2+ channels (LTCC) are altered in failing hearts, and increased LTCC activity is discussed as a cause of cardiomyopathy. We have shown that lack of the inhibitory G-protein isoform Gαi3 improves cardiac outcome and survival in a murine heart-failure model of cardiac β1-adrenoceptor (β1-AR) overexpression (β1-tg), while lack of the Gαi2 isoform was detrimental in the same heart-failure model. Given the potential role of LTCC and their modulation by β-adrenergic signalling, we now analysed ventricular ICaL in β1-tg mice and in β1-tg mice lacking either Gαi2 or Gαi3. Using the patch-clamp technique, we recorded whole-cell ICaL in ventricular myocytes freshly isolated from adult mice. Compared to age-matched wild-type littermates, basal ICaL was reduced in myocytes from β1-tg mice both under basal conditions (- 8.1 ± 1.6 vs. - 5.5 ± 1.5 pA/pF) and upon β-adrenergic stimulation with 1 µM isoproterenol (- 14.3 ± 5.6 vs. - 7.4 ± 1.9 pA/pF). Lack of Gαi3 normalised basal ICaL to nearly wild-type levels (- 7.5 ± 1.6 pA/pF), while β-adrenergic response remained attenuated (- 9.5 ± 3.6 pA/pF). In contrast, the absence of Gαi2 did not restore basal ICaL (- 5.7 ± 1.8 pA/pF), but restored the β-adrenergic response of ICaL, with the difference from basal current even exceeding that in wild-type mice (- 12.2 ± 2.9 pA/pF).We propose that by restoring basal ICaL, Gαi3 deficiency might contribute to the restoration of contractility in β1-tg mice, while maintaining attenuation of the ICaL response upon β-adrenergic stimulation protects against deleterious effects mediated by enhanced β-AR signalling. In contrast, restored and even enhanced ICaL response to β-adrenergic stimulation might contribute to detrimental effects of Gαi2 deficiency observed in β1-tg mice previously.
期刊介绍:
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.